[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":340},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,71,108,132,154,175,201,222,245,268,290,311],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100614380","natural-history-of-photoreceptor-degeneration-in-ush1b-clinical-parameters-and-validation-of-functional-vision-tests-in-myo7a-100614380",false,"NCT07278843","Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests in MYO7A","Natural History of Photoreceptor Degeneration Related to USH1B: Clinical Parameters and Validation of Functional Vision Tests in MYO7A","MYO7A","Inclusion Criteria:\n\n* Be at least 3 years old;\n* Have a clinical diagnosis of USH1 in both eyes, meaning subjects with congenital profound deafness, vestibular dysfunction, and rod dystrophy, carrying biallelic class 4 or 5 variants in the MYO7A gene;\n* Be affiliated with or beneficiary of a social security system (according to article L1121-8-1 of the French Public Health Code);\n\nFor participants in the MOST-VR mobility test and VR-ViSA visual search test (Streetlab), additional criteria apply:\n\n* Sufficient knowledge of spoken and signed French to ensure understanding of tasks and instructions;\n* Have a cochlear implant allowing comprehension of auditory instructions for the virtual reality mobility test and a MMSE score ≥ 20\u002F25;\n* Age between 18 and 75 years.\n\nExclusion Criteria:\n\n* Unable to participate in all study visits;\n* Expected to enter an experimental treatment trial at any time during this study;\n* Presence of ocular conditions that may affect eye status other than retinitis pigmentosa (e.g., history of retinal detachment, glaucoma, vein occlusion, diabetic retinopathy, etc.);\n* Participation in the previous gene replacement trial (USHSTAT, NCT01505062);\n* Pregnant, delivering, or breastfeeding women (according to article L1121-5 of the French Public Health Code);\n* Persons deprived of liberty by judicial or administrative decision (article L1121-6 of the French Public Health Code);\n* Adults under legal protection measures or unable to provide consent (article L1121-8 of the French Public Health Code).\n\nFor participants in the MOST-VR mobility and VR-ViSA visual search tests, the following non-inclusion criteria apply:\n\n* MMSE score without visual items ≤ 20\u002F25;\n* Physical or cognitive impairment that could interfere with mobility;\n* Medication that may cause motor, visual, or cognitive disorders (e.g., APS, neuroleptics) or interfere with study assessments.","ALL","3 Years","75 Years",{"count":21,"type":22},60,"ESTIMATED","48 Months","OBSERVATIONAL","Inherited retinal diseases (IRDs) are a group of degenerative disorders that cause progressive vision loss. Retinitis pigmentosa (RP) is the most common form, with a global prevalence of approximately 1 in 4,500. About 20-30% of these cases are syndromic, most notably Usher syndrome (USH), which combines hearing loss with visual impairment. Usher syndrome type 1 (USH1), the most severe form, presents at birth with profound sensorineural hearing loss, vestibular areflexia, and early-onset retinal degeneration. Biallelic mutations in the MYO7A gene, which define the USH1B subtype, account for 70% of USH1 cases. There is currently no treatment available for this serious condition. The objective of the study is to characterize the natural history of retinal degeneration in USH1B patients and to validate functional vision tests using virtual reality and patient-reported outcome questionnaires.",[27],"Usher Syndrome",[29,30,31,32,33],"Retina","Genetic mutation","Inherited disease","Retinis pigmentosa","Usher syndrome","RECRUITING","2026-02-09",{"date":37,"type":38},"2026-02-10","ACTUAL",{"date":40,"type":38},"2025-10-13",{"date":42,"type":22},"2032-09",{"name":44,"class":45},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":46},"100615467","implementation-and-evaluation-of-a-post-diagnostic-announcement-protocol-at-the-crmr-referet-quinze-vingts-hospital-100615467","NCT07292987","Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital","Implementation and Evaluation of a Post-diagnostic Announcement Protocol at the CRMR RefeRet of the Quinze-Vingts National Ophthalmology Hospital","RP-DIAG","Inclusion Criteria:\n\n* Diagnosed with retinitis pigmentosa (RP) and followed at the Quinze-Vingts Rare Eye Disease Center, with diagnosis made after the project begins\n* Aged 18 to 65 years\n* Male or female\n* French-speaking\n* Have a phone number\n* Reside in France\n\nExclusion Criteria:\n\n* Pregnant women\n* Participants enrolled in a therapeutic clinical trial within the past 12 months\n* Individuals deprived of liberty by judicial or administrative decision\n* Adults under legal protection or unable to provide informed consent\n* Individuals with other medical conditions or taking treatments that could interfere with study evaluations","18 Years","65 Years",{"count":58,"type":22},80,"INTERVENTIONAL",[61],"NA","This study explores whether adding early nurse-led and psychological support after the diagnosis of retinitis pigmentosa (RP) can improve patient experience and emotional well-being. RP is a rare, progressive eye disease often diagnosed after a long and difficult process, and receiving the diagnosis can be emotionally distressing.\n\nEighty newly diagnosed adults will be randomly assigned to either usual care or an enhanced pathway that includes early follow-up with a nurse, structured emotional monitoring, and a psychologist visit at six months.\n\nThe study aims to determine if this structured support improves patient satisfaction and reduces anxiety and depression compared with standard care.",[64],"Retinitis Pigmentosa (RP)",{"date":37,"type":38},{"date":67,"type":38},"2025-12-01",{"date":69,"type":22},"2028-01",{"name":44,"class":45},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":59,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":46},"100372409","high-resolution-high-speed-multimodal-ophthalmic-imaging-100372409","NCT04129021","High Resolution, High-speed Multimodal Ophthalmic Imaging","High Resolution and High Speed Multimodal Ophthalmic Imaging","IMA-MODE","Inclusion Criteria:\n\n* People over 18\n* Patient with a pathology affecting the eye or healthy volunteer\n* Participant who signed the consent\n* Beneficiaries of the health insurance\n\nExclusion Criteria:\n\n* Patients with a history of photosensitivity.\n* Patients who have just received a photodynamic therapy treatment (\n* Patients taking drugs with photosensitivity as a side effect.\n* Persons with pacemakers or other implanted electronic medical device\n* Patients with viral conjunctivitis or any other infectious disease.\n* Patients with skin lesions on the neck or forehead\n* Patients at high risk of damage from optical radiation, such as aphakic patients, or patients with decreased sensitivity to light due to fundus disease.\n* Pregnant or lactating women\n* Participant unable to be followed throughout the study\n* Vulnerable people\n* Subjects with predisposition to closure of the iridocorneal angle",true,{"count":81,"type":22},1200,[61],"Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging. However, current clinical imaging systems are limited in resolution, speed, or access to certain structures of the eye.\n\nThe use of a high-resolution imaging system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many microstructures of the eye: photoreceptors, vessels, nerve bundles in the retina, cells and nerves in the cornea.\n\nThe use of a high-speed acquisition imaging system makes it possible to detect functional measurements such as the speed of blood flow. The combination of data from multiple imaging systems to obtain multimodal information is of great importance for improving the understanding of structural changes in the eye during a disease.\n\nThe purpose of this project is to observe structures that are not detectable with routinely used systems.",[85,86,87,88,89,90,91,92,93,94,95,96,97,98,99],"Retinitis Pigmentosa","Maculopathy, Age Related","Macular Dystrophy","Macular Edema","Retinal Detachment","Retinal Degeneration","Glaucoma","Vascular Inflammation","Hypertension","Stroke","Diabetes","Corneal Dystrophy","Keratoconus","Dry Eye","Trauma","2025-11-17",{"date":102,"type":38},"2025-11-18",{"date":104,"type":38},"2019-07-03",{"date":106,"type":22},"2027-07",{"name":44,"class":45},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":79,"sex":17,"minAge":55,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":59,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":46},"100592148","feasibility-and-tolerability-study-of-smart-contact-lens-with-healthy-subjects-and-patients-with-stargardts-disease-100592148","NCT06989658","Feasibility and Tolerability Study of Smart Contact Lens With Healthy Subjects and Patients With Stargardt's Disease","Feasibility and Tolerability Study of Wearing a Miniaturized Smart Contact Lens With Healthy Subjects and Patients With Stargardt's Disease","RE-SEE","Inclusion Criteria:\n\nPatients with Stargardt disease\n\n* Age: 18 - 70 ;\n* Juvenile form of Stargardt's disease manifested by decreased visual acuity;\n* Visual acuity greater than or equal to 20\u002F400 in binocular vision;\n* MMSE score without visual item ≥ 20\u002F25 ;\n* Eyes whose palpebral opening and ocular surface and its appendages allow the wearing of a scleral lens;\n* Sufficient knowledge of the French language.\n* Ability to give express, free and informed consent in person, after having received adequate information;\n* Ability to comply with protocol requirements;\n* Person covered by Health Insurance.\n\nHealthy volunteers:\n\n* Age: 18 - 70 years;\n* Age- and sex-matched healthy volunteers to subjects with Stargardt's disease (± 5 years);\n* MMSE score with visual items ≥ 25\u002F30 ;\n* Eyes with palpebral opening and ocular surface and appendages suitable for scleral lens wear;\n* Visual acuity of at least 10\u002F10 in binocular vision;\n* Sufficient knowledge of the French language;\n* Ability to give personal, express, written, free and informed consent after receiving adequate information ;\n* Ability to comply with protocol requirements;\n* Person covered by Health Insurance.\n\nExclusion Criteria:\n\nFor all participantsPersons referred to in articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons : pregnant women, parturients, nursing mothers, persons deprived of liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or curatorship);\n\n* Participants with neurodegenerative diseases or any other disease that could interfere with the planned evaluations during this study;\n* Participants with ophthalmological diseases other than Stargardt's disease;\n* Participants with a history of cleft palate, corneal infection, irregular cornea (such as keratoconus) and severe dry eye syndrome as determined by the ophthalmologist;\n* Participants allergic or sensitive to methyl acrylic poly methacrylate (PMMA) or to any of the components of the Re-See lens;\n* Participants allergic to tropicamide, atropine or its derivatives\n* Participants at risk of angle-closure glaucoma;\n* Participants allergic to sodium fluorescein;\n* Suspicion of transmissible spongiform encephalopathy;\n* Medications that may cause motor, visual or cognitive disorders (neuroleptics, etc.) or that may interfere with study evaluations;\n* Participation in another clinical trial that could interfere with the present study;\n* Inability to follow instructions or read. ☞Wearing glasses or contact lenses is not a non inclusion criterion.","70 Years",{"count":118,"type":22},32,[61],"Oculometry is becoming increasingly popular in fields such as enhanced reality and healthcare, but remains limited by complex devices that are poorly adapted to the needs of users, particularly the visually impaired. This research proposes to explore a smart contact lens (SCL)-based system to overcome these limitations, particularly for people with central visual deficits such as Stargardt's disease.",[122],"Stargardt Disease","NOT_YET_RECRUITING","2025-09-12",{"date":126,"type":38},"2025-09-18",{"date":128,"type":22},"2025-10",{"date":130,"type":22},"2028-02",{"name":44,"class":45},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100602013","describe-the-progression-of-inflammatory-orbitopathy-and-the-biological-progression-of-patients-receiving-second-line-treatment-100602013","NCT07117981","Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment","Treatment of Graves' Orbitopathy in Patients Failing Corticosteroid Therapy: Multicenter National Retrospective Study- Basedow","HZN-IIT","Inclusion Criteria:\n\n* Patients aged 18 and older with moderate to severe orbitopathy;\n* Patients followed in endocrinology with the goal of achieving euthyroidism;\n* Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS);\n* Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy;\n* Patients with a CAS ≥ 3 or CAS \\\u003C3 with moderate to severe orbitopathy (according to EUGOGO);\n* Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line treatment;\n* Patients who are not opposed to the reuse of their health data.\n\nExclusion Criteria:\n\n* Patients who have undergone bone or fat decompression surgery;\n* Patients with severe corneal involvement (Grade B or C; NO SPECS classification);\n* Patients with optic neuropathy (Grade B and C; NO SPECS classification);\n* Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy;\n* Patients who have opposed the reuse of their health data.",{"count":141,"type":22},100,"Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).",[144],"Basedow Disease","2025-08-12",{"date":147,"type":38},"2025-08-15",{"date":149,"type":38},"2024-11-01",{"date":151,"type":22},"2025-12",{"name":44,"class":45},9,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":59,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":172,"leadSponsor":174,"locationsCount":4},"100600719","100-high-myopia-patient-reported-outcomes-pro-and-performance-outcomes-perfo-100600719","NCT07101146","100 High Myopia Patient-reported Outcomes (PRO) and Performance Outcomes (PERFO)","Pathological Myopia and Quality of Life: An Exploratory Study of Patient Outcomes and Perceptions","PPO100","Inclusion Criteria:\n\nPatients with pathological myopia and diffuse choroidal atrophy (DCA, Cat. 2 Meta PM)\n\n* Age ≥ 18 years and ≤ 55 years;\n* Patient consenting to be included in the study;\n* Examination and follow-up in at least one of the participating centers;\n* Severe pathological myopia with an axial length ≥ 26.5 mm in both eyes;\n* Presence of diffuse atrophy (category 2 of the Meta-PM classification) in the better eye;\n* Affiliated with or covered by a social security system.\n\nPathological myopic patients with patch choroidal atrophy (PCA,\n\nCat. 3 Meta PM):\n\n* Age ≥ 18 years and ≤ 55 years;\n* Patients who consent to be included in the study;\n* Examination and follow-up at least one of the participating centers;\n* High myopia with an axial length ≥ 26.5 mm in both eyes;\n* Presence of patch atrophy (category 3 of the Meta-PM classification) in the better eye;\n* Affiliated with or beneficiary of a social security system.\n\nExclusion Criteria:\n\n* Identified genetic syndromic myopia, including Stickler syndromes type 1 and 2 (collagen 2A1 and 11A1), Marfan syndrome (fibrillin), Ehler-Danlos syndrome type 4 (lysyl-protocollagen hydroxylase), and Knobloch syndrome (collagen 18A).\n* Patient unwilling to participate or be followed up at one of the participating centers.\n* Binocular visual acuity ≥ 1 logMar (\\\u003C0.1 on the decimal scale).\n* Media opacities preventing quality imaging, including cataracts.\n* Patients benefiting from legal protection measures.\n* Pregnant or breastfeeding women.\n* Individuals who may not be able to tolerate the driving simulator.","55 Years",{"count":141,"type":22},[61],"Prospective, longitudinal, interventional, exploratory, non-randomized, single-center study including patients with pathological myopia .",[167],"High Myopia","2025-08-01",{"date":170,"type":38},"2025-08-03",{"date":128,"type":22},{"date":173,"type":22},"2028-11-30",{"name":44,"class":45},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":79,"sex":17,"minAge":55,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":59,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100592174","study-of-human-ocular-hemodynamics-by-holography-dopple-100592174","NCT06989996","Study of Human Ocular Hemodynamics by Holography Dopple","HoLoEye","Inclusion Criteria:\n\nCriteria common to both populations ( patients and healthy volunteers) :\n\n* Age ≥ 18 years and \\\u003C 75 years;\n* Having received informed information about the study and having signed a consent to participate in the study;\n* Affiliated or covered by social security\n\nCriteria for healthy volunteers :\n\nNo ocular or systemic disease deemed to affect ocular circulation by an investigator\n\nSpecific criteria for patients:\n\n* Subjects usually followed at one of the recruiting centers;\n* Patients with chronic glaucoma, for whom a therapeutic modification is planned in the short term;\n* Patients with carotid stenosis;\n* Patients with choroidal pathology: pachychoroidism having led to pigment epithelium anomalies.\n\nExclusion Criteria:\n\n* For all participants:\n* Persons covered by articles L1121-5 to L1121-8 of the CSP (all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial decision or administrative decision, minors, and persons under legal protection: guardianship or curatorship);\n* Women of childbearing age not using an effective method of contraception, or positive pregnancy test (blood or urine);\n* Participants allergic to tropicamide when using pupillary dilatation;\n* Inability of the subject to maintain a stable sitting position for research procedures;\n* Temporary contraindication to HoloDoppler:\n\n  * Patient suffering from viral conjunctivitis or any other infectious disease;\n  * Patient with skin lesions on the neck or forehead, for which contact with a chin strap is not recommended.\n* Impossibility of making acquisitions of interest (e.g. due to a pupil diameter that is too small, advanced cataracts, nystagmus, etc.).\n* Wearing glasses or contact lenses to correct a refractive disorder is not considered a criterion for non-inclusion.","74 Years",{"count":184,"type":22},148,[61],"Prospective, interventional, non-randomized, open-label study, multi-center, Gehan-designed study with sequential inclusions in each subgroup, ranging from 4 subjects to a maximum 37 subjects per subgroup included",[91,188],"Retinal Vascular Disorder",[190,191,192],"glaucoma","pachychoroid,","carotid stenosis","2025-05-16",{"date":195,"type":38},"2025-05-25",{"date":197,"type":22},"2025-06",{"date":199,"type":22},"2028-06",{"name":44,"class":45},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":79,"sex":17,"minAge":55,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":59,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":46},"100591100","ocular-examination-at-cell-resolution-with-optical-transmissiontomography-100591100","NCT06976034","oCular Examination at Cell RESolution With Optical TransmissionTomography","CERES-OTT","Inclusion Criteria:\n\nFor Patients:\n\n* 200 subjects aged 18 to 80 years;\n* Male or female;\n* with an ocular disease affecting the cornea, ocular surface, lens (cataract) or glaucoma, or requiring refractive surgery or post-refractive surgery follow-up;\n* Are covered by the French Assurance Maladie;\n* Have signed an express, free and informed consent form.\n\nFor Healthy volunteers:\n\n* 100 subjects aged 18 to 80 years;\n* Male or female;\n* Healthy subjects with no known pathology directly or indirectly affecting ocular structures;\n* Covered by the French Assurance Maladie.\n* Having signed an express, free and informed consent form.\n\nExclusion Criteria:\n\nFor all participants:\n\n* Inability to hold a still position on a standard ophthalmic chin rest;\n* Conjunctivitis or other contagious contact disease in active phase;\n* Having an implanted pacemaker or other electronic medical device;\n* Having a predisposition to iridocorneal angle closure;\n* Vulnerable persons or persons under legal protection (pregnant or breast-feeding women; persons under guardianship,","80 Years",{"count":210,"type":22},300,[61],"Understanding the pathogenesis of eye diseases has benefited greatly from recent advances in ophthalmic imaging. However, current clinical imaging systems, such as optical coherence tomography (OCT), are limited in terms of resolution, acquisition speed or access to certain eye functions. Our team has participated in the development of a new generation of imaging technology known as optical transmission tomography (OTT), which enables imaging of the anterior parts of the eye with high cellular resolution, a wide field of view and reduced examination delay.",[214],"Glaucoma Associated With Other Ocular Disorders","2025-05-15",{"date":193,"type":38},{"date":218,"type":38},"2024-11-12",{"date":220,"type":22},"2029-11-12",{"name":44,"class":45},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":79,"sex":17,"minAge":230,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":59,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":4},"100541746","impact-of-age-related-macular-degeneration-on-daily-living-activitie-100541746","NCT06333873","Impact of Age-related Macular Degeneration on Daily Living Activitie","Validation of Standardized Tasks and Questionnaires to Evaluate and Understand the Impact of Age-related Macular Degeneration on Daily Living Activitie","AMDAY","Inclusion Criteria:\n\n* General criteria for healthy volunteers and AMD patients:\n\n  * Male \u002F Female participant,\n  * Age ≥ 50 at inclusion,\n  * Able and willing to provide written informed consent and comply with the study protocol, visits and assessments,\n  * Quality of AO imaging as assessed by rtx1 camera, ● deemed adequate according to the study physician,\n  * Membership of a social security scheme or beneficiary of such a scheme.\n* Specific criteria for the AMD group:\n\n  * Geriatric Depression Scale (GDS) questionnaire score ≤ 10 A COGEVIS questionnaire score ≥ 24\u002F30\n  * Visual acuity greater than 4\u002F10ths\n* General criteria for healthy volunteers:\n\n  * No detectable visual pathologies\n  * Best monocular visual acuity (corrected to 100% of the contrast) ≥ 8\u002F10ths before age 70 and ≥ 6\u002F10ths after.\n  * MMSE score ≥ 20\n* Specific criteria for the group of healthy volunteers with central microdrusens:\n\n  * No detectable visual pathologies other than the presence of central microdrusens.\n  * Best monocular visual acuity (corrected to 100% contrast) ≥ 8\u002F10th before age 70 and ≥ 6\u002F10th after.\n  * MMSE score ≥ 20\n\nExclusion Criteria:\n\n* Pregnant, parturient or breast-feeding women,\n* Subjects taking medication likely to cause motor, visual, vestibular or cognitive disorders (PSA, neuroleptics, etc.) or who could interfere with the study examinations cannot be included in this study,\n* Environmental opacity or eye movement disorders (nystagmus) which, in the opinion of the investigator, interfere with the quality of retinal imaging data.\n* Any concomitant intraocular condition in the study eye (e.g. glaucoma or cataract) that, in the opinion of the investigator, would require surgical intervention during the study to prevent or treat vision loss that may result from this condition or affect the interpretation of study results,\n* Known systemic disease which, in the opinion of the investigator, would preclude active participation in the study,\n* Participation in any other therapeutic study evaluating a drug,\n* Cognitively impaired subjects, illiterate subjects and subjects who do not speak the national language.\n* Subjects with dyslexic reading disorders,\n* Subjects subject to a reinforced protection measure or legal safeguard (curatorship, guardianship).","50 Years",{"count":232,"type":22},120,[61],"The complex and variable course of age-related diseases makes it all the more necessary to carry out personalised, reasoning-based examinations to improve the personalised assessment and management of AMD. However, functional assessment of AMD is most often based solely on visual acuity, and classifications of AMD are based solely on structural markers. There is therefore a need to improve the detection and functional assessment of this vision-threatening eye disease, by complementing and extending the standard assessments of clinical outcomes (COA)",[236],"Age-Related Macular Degeneration","2024-03-20",{"date":239,"type":38},"2024-03-27",{"date":241,"type":22},"2024-06",{"date":243,"type":22},"2029-06",{"name":44,"class":45},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":59,"phases":254,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":4},"100510616","prospective-cohort-of-non-infectious-intermediate-posterior-or-panuveitis-100510616","NCT05928754","Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","CHRONOS","Inclusion Criteria:\n\nUVEITIS Patients:\n\n* Adult patients (≥ 18 years);\n* Non-infectious uveitis;\n* Intermediate, posterior or panuveitis;\n* Inflammatory activity requiring treatment with either one or more of the followings:\n\n  * Systemic corticosteroids or periocular or intravitreal injections of corticosteroids;\n  * Immunosuppressants: methotrexate, azathioprine, cyclosporine, etc.;\n  * Biotherapy: infliximab, adalimumab, tocilizumab;\n* Patients with health insurance;\n* Written Informed consent obtained at enrolment in the study.\n\nControl patients:\n\n* Adult patients (≥ 18 years);\n* Scheduled patients ( Non-urgente procedure) for cataract or vitreoretinal surgery;\n* Patients with health insurance;\n* Written Informed consent obtained at enrolment in the study.\n\nExclusion Criteria:\n\nUveitis Patients:\n\n* Isolated anterior uveitis ;\n* Inactive disease defined as:\n\n  * Absence of inflammatory chorioretinal and\u002For inflammatory retinal vascular lesion;\n  * Anterior chamber cell grade\\\u003C 0.5+;\n  * Vitreous haze grade \\\u003C0.5+;\n* Pregnant or breastfeeding woman at the inclusion visit;\n* Patient under legal protection (\" curatelle \" or \" tutelle \");\n* Patient denied freedom by a legal or administrative order.\n\nControl patients:\n\n* Pregnant or breastfeeding woman;\n* Unscheduled (urgent) cataract or vitreoretinal surgery;\n* Patient under legal protection (\" curatelle \" or \" tutelle \");\n* Patient denied freedom by a legal or administrative order.",{"count":253,"type":22},2000,[61],"prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and constitution of biological collection.",[257],"Non-infectious Uveitis",[259],"non-infectious uveitis","2023-06-26",{"date":262,"type":38},"2023-07-03",{"date":264,"type":22},"2023-09",{"date":266,"type":22},"2028-08",{"name":44,"class":45},{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":275,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":59,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":4},"100504564","large-cohort-of-1000-patients-with-severe-myopia-100504564","NCT05849974","Large Cohort of 1000 Patients With Severe Myopia","MyoCo1000","Inclusion Criteria:\n\n* Age ≥ 6 years\n* Severe myopia in at least one eye, defined as\n\n  * a refractive error ≤ -6.00 diopters OR\n  * an axial length ≥ 26.50 mm\n* Follow-up performed at at least one of the participating centers\n* Express consent to participate in the study\n* If age \\\u003C 18 years: express consent of the person(s) exercising parental authority\n* Affiliated or beneficiary of a health insurance\n\nExclusion Criteria:\n\n* Visual acuity \\\u003C 5 letters on the ETDRS (equivalent to \"finger count\" or less) in both eyes\n* Disorders of the transparent media in both eyes with opacities that may affect image quality\n* Syndromic myopia of genetic origin (Stickler syndrome type 1 and 2, Marfan syndrome, Ehler-Danlos disease type 4, Knobloch syndrome) or inherited retinal dystrophy (X-linked retinitis pigmentosa, congenital stationary night blindness of Schubert-Bornshein type, Bornholm eye disease)\n* Patient who does not wish to continue to be followed in one of the participating centers\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman","6 Years",{"count":277,"type":22},1000,[61],"The prevalence of myopia and severe myopia are increasing and will affect 50% and 10% of the population respectively. Severe myopia exposes an increased risk of glaucoma, cataract, retinal detachment and myopic maculopathy, a source of visual impairment.\n\nTo date, no European cohort study has been conducted to estimate the rate of these complications and to study the predictive parameters.",[281],"Myopia, Severe","2023-05-22",{"date":284,"type":38},"2023-05-23",{"date":286,"type":22},"2023-06",{"date":288,"type":22},"2038-05",{"name":44,"class":45},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":79,"sex":17,"minAge":55,"maxAge":208,"enrollmentInfo":298,"targetDuration":4,"studyType":59,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":4},"100496710","streetlab-assessment-tool-of-activities-daily-living-in-glaucoma-patient-100496710","NCT05747781","STReetlab Assessment Tool of Activities Daily Living in Glaucoma Patient","Validation of Standardized Tests Allowing the Evaluation of the Impacts of Glaucomatous Optic Neuropathy in Daily Life Activities","STRATAL-GL","Inclusion Criteria:\n\nGlaucoma patients:\n\n* Age: 18 - 80 years,\n* Visual acuity of at least 6\u002F10th binocular,\n* Patient followed at Quinze-Vingts and presenting with chronic stable glaucoma defined by the glaucoma ophthalmologist,\n* MMSE questionnaire score ≥ 25\u002F30 or ≥ 16\u002F25 (if the patient no longer drives),\n* Ability to give consent and comply with the study protocol,\n* Person with Social Security coverage.\n* Recruitment of glaucoma patients will be based on the criteria defined by the HPA classification (Appendix) on the basis of the Humphrey visual field, for categorization of patients into three stages of optic neuropathy progression (early stage \"1\", moderate \"2\" and advanced \"3\").\n\nFor the optional roadside fitness visit (V4), specific inclusion criteria will be required for this study: the roadside assessment will be performed with volunteers (GL and VS) who report being:\n\n* Always drivers in possession of a valid driver's license,\n* Driven at least 500 km in the past year.\n\nHealthy volunteer:\n\n* Age: 18 - 80 years.\n* Age and sex matching between healthy volunteers and glaucoma patients (± 5 years).\n* MMSE questionnaire score ≥ 25\u002F30.\n* Visual acuity of at least 10\u002F10th in binocular.\n* Ability to give consent and comply with the study protocol.\n* Person with a Social Security plan.\n\nFor the roadside fitness visit (V4), specific inclusion criteria will be required for this study: the roadside assessment will be performed with volunteers who declare themselves:\n\n* Always drivers in possession of a valid driver's license,\n* Driven at least 500 km in the past year.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Inability to personally give consent.\n* Participants will not have neurodegenerative diseases or any other disease that could interfere with the assessments planned during this study.\n* Participants will not have any other ophthalmologic diseases other than glaucoma.\n* Drug treatments that may cause motor, visual, or cognitive impairment (PSAs, neuroleptics, etc.) or that may interfere with the study assessments.\n* Condition that limits ability to move.\n* Inability to read.",{"count":141,"type":22},[61],"The impact of glaucomatous optic neuropathy on the daily life of patients is poorly characterized and does not benefit from standardized tests.\n\nThe development and validation of new tests could be used to assess the efficacy of innovative treatments for visually impaired patients and\u002For optimize management strategies.",[302],"Optic Neuropathy","2023-02-17",{"date":305,"type":38},"2023-02-28",{"date":307,"type":22},"2023-03-01",{"date":309,"type":22},"2027-03-31",{"name":44,"class":45},{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":319,"targetDuration":321,"studyType":24,"phases":4,"briefSummary":322,"conditions":323,"keywords":325,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":339},"100413602","natural-history-study-of-usher-syndrome--light4deaf--100413602","NCT04665726","Natural History Study of Usher Syndrome ( Light4Deaf )","Natural History Study of Usher Syndrome in a Cohort of Patients Followed Longitudinally for 5 Years","Light4Deaf","Inclusion Criteria:\n\n* Patient with a molecular diagnosis of Usher syndrome type I, II or III or a clinical diagnosis of Usher syndrome type I, II or III which will then be confirmed by a molecular diagnosis\n* Health insurance beneficiary\n* Informed consent signed by the patient or their legal representatives\n\nExclusion Criteria:\n\n• Patient or his\u002Fher legal representatives unable to understand the study and for whom informed consent cannot be obtained",{"count":320,"type":22},400,"5 Years","Clinical centres in the LIGHT4DEAF consortium have developed and will continue to improve a reliable, early molecular diagnosis and protocols for full clinical characterisation of Usher syndrome, which will be valuable for the foreseen USH clinical trials. The clinical arm of the project aims at performing a deep-phenotyping of retinal degeneration, hearing loss, vestibular dysfunction, neurocognitive ability of subects with a molecular diagnosis of any Usher syndrome. Functional and structural parameters for retinal, auditory, and vestibular impairments are followed overtime to document the natural history of the disease and establish relevant clinical endpoint for disease progression that may be useful for future clinical trials.",[324],"Usher Syndromes",[326,327,328,329,330],"Usher syndrome,","Natural history study for retinal degenetation,","Deep-phenotyping,","Hearing loss,","Vestibular dysfunction","2020-12-07",{"date":333,"type":38},"2020-12-14",{"date":335,"type":38},"2017-06-08",{"date":337,"type":22},"2027-06-08",{"name":44,"class":45},4,""]